The effects of insulin sensitizers on the cardiovascular risk factors in women with polycystic ovary syndrome

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in pre-menopausal women characterized by menstrual cycle disturbances, chronic anovulation, and clinical and/or biochemical hyperandrogenism. Although, the primary etiology of PCOS remains unknown, insulin resistance/hyperinsulinemia plays a pivotal role in the pathogenesis of the syndrome. A growing body of recent data support that women with PCOS have displayed an increased prevelance of cardiovascular disease (CVD) risk factors putting potentially at a hight risk for heart disease. Most of these CVD risk factors are etiologically correlated with insulin resistance/hyperinsulinemia, highlighting the role of insulin sensitizers in the therapeutic quiver for the chronic treatment of PCOS. In this review, we discuss the current literature on the CVD risk factors in PCOS and the influence of insulin sensitizers upon these risk factors.

Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome

“…Chronic anovulation causes the endometrium to be exposed to prolonged mitogenic effects of estrogen, unopposed by the inhibitory effects of progesterone, which are present in the luteal phases of normal menstrual cycles. In addition to problems such as infertility, hirsutism, and disturbances to the menstrual cycle, recent reports show that women with PCOS have an increased prevalence of diabetes mellitus, hypertension, and cardiovascular disease (CVD) risk factors, potentially putting them at a high risk for heart disease [1,2].…”

Basic and Meal Stimulated Plasma GIP Levels are Higher in Lean PCOS Women with FAI over 5

“…On the basis of our survey, we cannot draw a conclusion if higher GIP level among PCOS women might be linked with impaired insulinotropic effect of the incretin. It should be evaluated by GIP administration during the period of hyperglycemic clamp and assay of the incretin effect [22]. Another hypothesis of the increased GIP level might be a state of decreased GIP activity and in effect a compensatory mechanism of exaggerated secretion is observed [23].…”

Το Φαινόμενο Της Ινκρετίνης Σε Γυναίκες Με Σύνδρομο Πολυκυστικών Ωοθηκών

“…είναι υπέρβαρες ή παχύσαρκες, εµφανίζουν συχνά µεταβολικές διαταραχές όπως δυσλιπιδαιµία και υπεργλυκαιµία και τέλος παρουσιάζουν αυξηµένο κίνδυνο εµφάνισης Σ/∆ τύπου 2 και καρδιαγγειακών παθήσεων. 185,186,187,200,201,202,203,204,205 Η αντίσταση στην ινσουλίνη είναι σηµαντική τόσο στην παθογένεια του Σ.Π.Ω. όσο και στην προοδευτική εµφάνιση στον Σ/∆ τύπου 2.…”